Lipoprotein lipase activity of adipose tissue, skeletal muscle and post-heparin plasma in primary endogenous hypertriglyceridaemia: relation to lipoprotein pattern and to obesity. 1982

M R Taskinen, and E A Nikkilä, and T Kuusi

The lipoprotein lipase (LPL) activity was determined from heparin eluates of adipose tissue and skeletal muscle and from post-heparin plasma of sixty-five males with hypertriglyceridaemia and of seventy males with normal serum lipid levels. The patients were subgrouped by their lipoprotein concentrations into types 2b, 4 and 5. The mean LPL activity of adipose tissue (per tissue weight) of nonobese type 2b, 4 and 5 patients was reduced to 54%, 41% and 13%, respectively, of the corresponding value of normolipidaemic men. On the other hand, among obese hyperglyceridaemic men only those with type 5 showed a decreased LPL activity in adipose tissue (44%). The mean skeletal muscle LPL was subnormal in nonobese type 4 (55%) and in type 5 patients (34%) but was normal in type 2b and in obese type 4 patients. The post-heparin plasma LPL activity was significantly reduced in all nonobese hyperglyceridaemic groups but was normal in obese patients apart from cases with type 5 who had low values. One exceptional subject with type 5 had high post-heparin plasma LPL activity. It is concluded that a low LPL activity may be a crucial factor in the pathogenesis of hypertriglyceridaemia in nonobese subjects and in patients having type 5 disorder.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D006953 Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits. Hyperprebetalipoproteinemia,Hypertriglyceridemia, Familial,Carbohydrate Inducible Hyperlipemia,Carbohydrate-Inducible Hyperlipemia,Familial Hyperlipoproteinemia Type 4,Familial Type IV Hyperlipoproteinemia,Hyper prebeta lipoproteinemia,Hyperlipoproteinemia, Type IV,Carbohydrate Inducible Hyperlipemias,Carbohydrate-Inducible Hyperlipemias,Familial Hypertriglyceridemia,Hyperlipemia, Carbohydrate Inducible,Hyperlipemia, Carbohydrate-Inducible,Hyperlipemias, Carbohydrate Inducible,Hyperlipemias, Carbohydrate-Inducible,Hyperlipoproteinemias, Type IV,Inducible Hyperlipemia, Carbohydrate,Inducible Hyperlipemias, Carbohydrate,Type IV Hyperlipoproteinemia,Type IV Hyperlipoproteinemias,Type IV, Hyperlipoproteinemia
D006954 Hyperlipoproteinemia Type V A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I . Hyperchylomicronemia Late Onset,Hyperchylomicronemia With Hyperprebetalipoproteinemia, Familial,Hyperchylomicronemia, Late-Onset,Hyperlipemia, Combined Fat And Carbohydrate-Induced,Hyperlipemia, Mixed,Hyperlipidemia, Type V,Hyperlipoproteinemia Type 5,Hyperlipoproteinemia, Type V,Hyperchylomicronemia Late Onsets,Hyperchylomicronemia, Late Onset,Hyperchylomicronemias, Late-Onset,Hyperlipemia, Combined Fat And Carbohydrate Induced,Hyperlipemias, Mixed,Hyperlipidemias, Type V,Hyperlipoproteinemia Type 5s,Hyperlipoproteinemias, Type V,Late-Onset Hyperchylomicronemia,Late-Onset Hyperchylomicronemias,Mixed Hyperlipemia,Mixed Hyperlipemias,Type V Hyperlipidemia,Type V Hyperlipidemias,Type V Hyperlipoproteinemia,Type V Hyperlipoproteinemias
D008071 Lipoprotein Lipase An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34. Heparin-Clearing Factor,Lipemia-Clearing Factor,Diacylglycerol Lipase,Diglyceride Lipase,Post-Heparin Lipase,Postheparin Lipase,Postheparin Lipoprotein Lipase,Factor, Heparin-Clearing,Factor, Lipemia-Clearing,Heparin Clearing Factor,Lipase, Diacylglycerol,Lipase, Diglyceride,Lipase, Lipoprotein,Lipase, Post-Heparin,Lipase, Postheparin,Lipase, Postheparin Lipoprotein,Lipemia Clearing Factor,Lipoprotein Lipase, Postheparin,Post Heparin Lipase
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

M R Taskinen, and E A Nikkilä, and T Kuusi
April 1980, European journal of clinical investigation,
M R Taskinen, and E A Nikkilä, and T Kuusi
June 1979, Atherosclerosis,
M R Taskinen, and E A Nikkilä, and T Kuusi
January 1984, International journal of obesity,
M R Taskinen, and E A Nikkilä, and T Kuusi
February 1980, Biochemical Society transactions,
M R Taskinen, and E A Nikkilä, and T Kuusi
December 1968, Acta endocrinologica,
M R Taskinen, and E A Nikkilä, and T Kuusi
May 1984, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M R Taskinen, and E A Nikkilä, and T Kuusi
March 1979, Acta physiologica Scandinavica,
M R Taskinen, and E A Nikkilä, and T Kuusi
February 1987, The Journal of nutrition,
M R Taskinen, and E A Nikkilä, and T Kuusi
January 1999, Journal of endocrinological investigation,
Copied contents to your clipboard!